New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Health Sciences Group Division Introduces Tri-Xanthin; Safe Alternative to Ephedra Expected to Boost Sales

LOS ANGELES--Sept. 25, 2003--Health Sciences Group, Inc. (OTCBB: HESG), an integrated provider of innovative products and services to the nutraceutical, pharmaceutical, and cosmeceutical industries announced the launch of Tri-Xanthin(TM), a novel and proprietary weight-loss product produced by its Quality Botanical Ingredients (QBI) division. QBI is a leading manufacturer, processor and supplier of bulk botanical materials and nutritional ingredients.

Tri-Xanthin(TM) has the ability to boost the body's natural fat burning process. Each dosage of Tri-Xanthin(TM) delivers the exact clinically-studied amount of powerful fat-burning and energizing power of its three key components derived from standardized extracts of green tea, cocoa beans and the mate leaf. Green tea and cocoa bean extracts have been shown to raise metabolic rates and speed up the burning of fat calories while mate extract seems to improve mood and concentration, reduce anxiety, prevent mental fatigue, and prolong the thermogenic effects of fat burning.

Ephedra (or Ma Huang in its natural form) was, until recently, the most popular non-prescription ingredient for weight loss supplements and food products. Of late, the substance has been blamed for serious health problems and even deaths, causing much of the industry to abandon it and some regulators to ban it. Tri-Xanthin(TM) offers the same weight loss properties without the adverse side effects.

"We believe the market for this product has enormous potential which can translate to accelerated sales growth for QBI," said QBI President Joseph Schortz. "The popularity of ephedra illustrates the growing demand for weight loss products. Tri-Xanthin(TM) provides a similar effect to ephedra with a much more attractive safety profile. Our proprietary blend of these three special herbal extracts, chosen for their high thermogenic activity, creates opportunities for use in a wide variety of products. We expect Tri-Xanthin(TM) will have strong consumer appeal for use in drinks, tablets, capsules, energy bars or most any food product."

QBI is working with a number of food and supplement manufacturers to formulate new Tri-Xanthin(TM)-based products that should soon be available in grocery and natural food stores.

About Health Sciences Group, Inc.

Health Sciences Group, Inc., is an integrated provider of innovative products and services in the nutraceutical, pharmaceutical, and cosmeceutical industries offering value-added ingredients, bioactive formulations, and proprietary technologies used in nutritional supplements, functional foods and beverages, and skin care products. Its largest division is Quality Botanical Ingredients (QBI), a leading manufacturer, contract processor and supplier of bulk botanical materials and nutritional ingredients to the food, nutraceutical, pharmaceutical, cosmetic and pet food industries. QBI processes more than 500 herbs, dried fruits and vegetables, nutraceuticals and an extensive selection of concentrated herbal extracts, as well as standardized herbal extracts of guaranteed potency, in addition to various bioflavonoids, antioxidants and beehive products. In business for 20 years, QBI uses cryogenic (cold) processing at its New Jersey facility, and operates in accordance with voluntary food safety guidelines (called Good Manufacturing Practices) originally published by the U.S. Food & Drug Administration in 1997.

Its other divisions include XCEL Healthcare, a fully licensed, specialty compounding pharmacy delivering full service pharmacology solutions to customers with chronic ailments that require long-term therapy; and BioSelect Innovations, which develops and sells innovative, science-based products based on proprietary technologies in the areas of topical/transdermal drug delivery, cosmeceuticals, and integrative medicine to a global network of customers who manufacture and distribute compounded pharmaceuticals, functional foods, skin care products and cosmetics. For more information, visit

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, the independent authority of the special committee to act on the matters discussed, the successful negotiation of the potential acquisition and disposal of transactions described above, successful implementation of the company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.